Results 41 to 50 of about 17,985,271 (268)

Erectile dysfunction in men with diabetes (literature review). Part 2

Mìžnarodnij Endokrinologìčnij Žurnal, 2021
The second part of review article highlights modern views on the diagnosis and treatment of erectile dysfunction (ED) in men with diabetes mellitus (DM). Google Scholar and PubMed databases were used to search for literature sources. The role of comorbid
Е.V. Luchytskiy, V.E. Luchytskiy
doaj   +1 more source

Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors

Clinics, 2014
With advancing age, there is an increase in the complaints of a lack of a libido in women and erectile dysfunction in men. The efficacy of phosphodiesterase type 5 inhibitors, together with their minimal side effects and ease of administration ...
Sandra Léa Bonfim Reis, Carmita H.N. Abdo   +1 more
doaj   +1 more source

Phosphodiesterase 5 inhibitors and nitrergic transmission - from zaprinast to sildenafil

, 2001
Phosphodiesterase 5 terminates the cellular actions of the second messenger molecule cyclic GMP; inhibitors of phosphodiesterase 5 will therefore increase and prolong the actions of endogenous substances that signal via the cyclic GMP pathway, including ...
Gibson, A
core   +5 more sources

Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction

, 2005
Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of which three are available.
Zanni G, SALONIA , ANDREA, BRIGANTI , ALBERTO, Deho' F, Barbieri L, MONTORSI , FRANCESCO, Rigatti P   +6 more
core   +2 more sources

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy

, 2010
Mitchell S Buckley1, Robin L Staib1, Laura M Wicks1, Jeremy P Feldman21Department of Pharmacy, Banner Good Samaritan Medical Center, and 2Arizona Pulmonary Specialists Ltd, Phoenix, Arizona, USAAbstract: Pulmonary arterial hypertension (PAH) is a ...
null Robin Staib, Mitchell S Buckley, Jeremy Jeremy Feldman, null Laura Wicks, et al, null Mitchell Buckley, Robin L Staib, Laura M Wicks   +7 more
core   +1 more source

Glutathione‐Responsive Acyl‐Modifications for Targeted RNA Decaging and Prolonged Protein Synthesis

Angewandte Chemie, EarlyView.
The self‐immolation of disulfide‐based mRNA modifications in response to endogenous glutathione (GSH) promotes a gradual release of translatable mRNA within the cell, leading to improved nuclease resistance, tunable release properties, and a significant increase (up to 600%) of target protein production over time. This strategy offers an exciting proof
Mary E. Flood, Sathishkumar Kurusamy, Mark Berney, C. Mark Smales, Elizabeth M. Topp, Joanna F. McGouran, Steven Ferguson   +6 more
wiley   +2 more sources

Progressive Parkinsonism in PPP2R5D‐Related Neurodevelopmental Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT PPP2R5D‐related neurodevelopmental disorder (Houge–Janssens syndrome type 1) is a rare autosomal dominant condition characterized by macrocephaly, intellectual disability, and epilepsy. Progressive parkinsonism is an emerging adult phenotype that neurologists should be aware of since timely genetic diagnosis opens the door to disease‐modifying
Katerina Bernardi, Enrique Gonzalez Saez‐Diez, Joshua Rong, Beril Ay, Shabbir Merchant, Kathryn Yang, Darius Ebrahimi‐Fakhari   +6 more
wiley   +1 more source

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction

Pharmacy, 2015
It has been reported that patients frequently discontinue treatment for erectile dysfunction (ED) with phosphodiesterase type 5 inhibitors (PDE5Is) despite apparently good therapeutic results.
Connie C. J. Louizos, Peter K. Knight
doaj   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Microvascular Damage Is Associated With Carotid Wall Structural Changes in Systemic Sclerosis: A Capillaroscopy and Ultrasound‐Based Observational Study

Arthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by cardiovascular risk excess not fully explained by traditional factors. Whether the severity of microvascular damage correlates with structural subclinical atherosclerosis remains unclear. We investigated the relationship between nailfold videocapillaroscopy (NVC) abnormalities and carotid ...
Eugenio Capparelli, Luca Clerici, Francesco Lapia, Giusy C. Moltisanti, Eleonora Zaccara, Greta Pellegrino, Daniela Bompane, Francesca Capelli, Letizia Ferrami, Laura Castelnovo, Antonio Tamburello, Maria Sole Chimenti, Paola Faggioli, Antonino Mazzone   +13 more
wiley   +1 more source